30.08.17|Dror ReichWith two exits worth hundreds of millions of dollars to his name even before selling Kite Pharma for $12 billion dollars, just where will Arie Belldegrun aim next?
29.08.17|Dror ReichThe drug company is looking to diversify into cell therapy following declining hepatitis c drug sales